Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication

Epidermal growth factor receptor (EGFR) kinase domain duplication (KDD) has been identified as an oncogenic driver in 0.05% to 0.14% of non–small cell lung cancer (NSCLC) patients. However, little is known of the efficacy of EGFR tyrosine kinase inhibitors (TKIs) for such patients. Here, we report t...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirokawa, Esuteru, Watanabe, Satomi, Sakai, Kazuko, Takeda, Masayuki, Sato, Chihiro, Takahama, Takayuki, Nishio, Kazuto, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365001/
https://www.ncbi.nlm.nih.gov/pubmed/34240806
http://dx.doi.org/10.1111/1759-7714.14081
_version_ 1783738625062600704
author Hirokawa, Esuteru
Watanabe, Satomi
Sakai, Kazuko
Takeda, Masayuki
Sato, Chihiro
Takahama, Takayuki
Nishio, Kazuto
Nakagawa, Kazuhiko
author_facet Hirokawa, Esuteru
Watanabe, Satomi
Sakai, Kazuko
Takeda, Masayuki
Sato, Chihiro
Takahama, Takayuki
Nishio, Kazuto
Nakagawa, Kazuhiko
author_sort Hirokawa, Esuteru
collection PubMed
description Epidermal growth factor receptor (EGFR) kinase domain duplication (KDD) has been identified as an oncogenic driver in 0.05% to 0.14% of non–small cell lung cancer (NSCLC) patients. However, little is known of the efficacy of EGFR tyrosine kinase inhibitors (TKIs) for such patients. Here, we report the case of a 45‐year‐old Japanese woman with NSCLC positive for EGFR‐KDD (duplication of exons 18–25) who developed carcinomatous meningitis and showed a marked response to the EGFR‐TKIs erlotinib and osimertinib. As far as we are aware, this is the first report of EGFR‐TKI efficacy for carcinomatous meningitis in a NSCLC patient harboring EGFR‐KDD.
format Online
Article
Text
id pubmed-8365001
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-83650012021-08-23 Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication Hirokawa, Esuteru Watanabe, Satomi Sakai, Kazuko Takeda, Masayuki Sato, Chihiro Takahama, Takayuki Nishio, Kazuto Nakagawa, Kazuhiko Thorac Cancer Case Reports Epidermal growth factor receptor (EGFR) kinase domain duplication (KDD) has been identified as an oncogenic driver in 0.05% to 0.14% of non–small cell lung cancer (NSCLC) patients. However, little is known of the efficacy of EGFR tyrosine kinase inhibitors (TKIs) for such patients. Here, we report the case of a 45‐year‐old Japanese woman with NSCLC positive for EGFR‐KDD (duplication of exons 18–25) who developed carcinomatous meningitis and showed a marked response to the EGFR‐TKIs erlotinib and osimertinib. As far as we are aware, this is the first report of EGFR‐TKI efficacy for carcinomatous meningitis in a NSCLC patient harboring EGFR‐KDD. John Wiley & Sons Australia, Ltd 2021-07-09 2021-08 /pmc/articles/PMC8365001/ /pubmed/34240806 http://dx.doi.org/10.1111/1759-7714.14081 Text en © 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Hirokawa, Esuteru
Watanabe, Satomi
Sakai, Kazuko
Takeda, Masayuki
Sato, Chihiro
Takahama, Takayuki
Nishio, Kazuto
Nakagawa, Kazuhiko
Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
title Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
title_full Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
title_fullStr Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
title_full_unstemmed Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
title_short Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
title_sort durable response to egfr tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an egfr kinase domain duplication
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365001/
https://www.ncbi.nlm.nih.gov/pubmed/34240806
http://dx.doi.org/10.1111/1759-7714.14081
work_keys_str_mv AT hirokawaesuteru durableresponsetoegfrtyrosinekinaseinhibitorsinapatientwithnonsmallcelllungcancerharboringanegfrkinasedomainduplication
AT watanabesatomi durableresponsetoegfrtyrosinekinaseinhibitorsinapatientwithnonsmallcelllungcancerharboringanegfrkinasedomainduplication
AT sakaikazuko durableresponsetoegfrtyrosinekinaseinhibitorsinapatientwithnonsmallcelllungcancerharboringanegfrkinasedomainduplication
AT takedamasayuki durableresponsetoegfrtyrosinekinaseinhibitorsinapatientwithnonsmallcelllungcancerharboringanegfrkinasedomainduplication
AT satochihiro durableresponsetoegfrtyrosinekinaseinhibitorsinapatientwithnonsmallcelllungcancerharboringanegfrkinasedomainduplication
AT takahamatakayuki durableresponsetoegfrtyrosinekinaseinhibitorsinapatientwithnonsmallcelllungcancerharboringanegfrkinasedomainduplication
AT nishiokazuto durableresponsetoegfrtyrosinekinaseinhibitorsinapatientwithnonsmallcelllungcancerharboringanegfrkinasedomainduplication
AT nakagawakazuhiko durableresponsetoegfrtyrosinekinaseinhibitorsinapatientwithnonsmallcelllungcancerharboringanegfrkinasedomainduplication

Ejemplares similares